Missing year-one EBITDA is a documentation problem, not an execution problem

If your acquisitions are consistently missing EBITDA benchmarks in year one and you keep blaming integration friction, the actual problem is likely sitting in the PMS data that nobody properly looked at during diligence.

I spoke with someone who ran operations at a PE-backed DSO with 100+ locations. Every acquisition missed its year-one EBITDA target, and integration was the excuse. But most of what got blamed on integration was already there before the deal closed. It just wasn't documented in the deal room, so when the ops team spent months on discovery instead of execution they got blamed for slow results even though they walked in with zero visibility into what needed fixing.

Whether it's lapsed patients representing hundreds of thousands in recoverable revenue sitting in the PMS, or unscheduled treatments accumulating for months, or provider variance where one doctor produced at half the rate of another doing identical procedures. None showed up in trailing EBITDA. The deal closed based on assumptions and the ops team spent six months figuring out what was broken. So by the time discovery finished and improvements started flowing through financials, nine months had passed. The practice had missed its target, the ops team was taking heat, and the deal team moved on to the next acquisition with the exact same costly blind spots.

The gap is that operational opportunities live in the PMS as patient-level patterns that don't show up on the P&L. Standard financial diligence has no way to find them even though they're completely documentable and executable.

Operations knows what to look for in the PMS but doesn't have bandwidth to do forensic analysis on top of running the existing portfolio. Meanwhile, finance teams know how to build models but don't know which PMS reports reveal operational upside or how to translate patient patterns into recoverable revenue at the deal multiple.

A pre-close operational diagnostic solves this: PMS-level forensics documented in financial terms your deal team can underwrite, with an execution roadmap for ops from Day 1 onwards. Lapsed recall becomes recoverable revenue with patient counts and capture timeline, unscheduled treatment becomes EBITDA capture with ownership assigned, and provider variance becomes margin improvement with root cause and protocol fix.

When that exists alongside financial diligence, your models stop being built on assumptions and start being built on documented baselines. Your ops team walks in knowing what to execute instead of spending a quarter on discovery. So the acquisition that would've missed its target now has quantified proof of what was inherited and what capturing it requires.

That's why the systematic EBITDA misses aren't an execution problem. They're a documentation problem. You're inheriting operational gaps that exist before you close, modeling improvements without validating what actually needs fixing, and discovering the real operational picture six months too late.